OWL Oncology Research
Haley Stoltzman is a seasoned professional with extensive experience in business operations and implementation management. Currently serving as Senior Business Operations Manager at OWL Oncology Research since October 2022, Stoltzman previously held positions including Enterprise Implementation Manager at ClearCompany Talent Management Software, where responsibilities included consulting with clients on implementation projects and leading API integration efforts. Additional roles include Director of Operations at Stoltzman Consulting, where financial and human resources operations were managed, and Project Manager at IHS, focusing on Agile methodologies and customer churn reduction. Early career experience includes positions in commodity trading at JBS Trade Group and various roles at the Town of Windsor Colorado. Stoltzman holds a Bachelor of Arts in Economics from Washington and Lee University.
This person is not in any teams
This person is not in any offices
OWL Oncology Research
OWL Oncology Research®, a Functional Service Provider (FSP), is a global network of hundreds of experienced clinical research experts specializing in oncology and rare disease trial monitoring, management, consulting and oversight. We deliver the highest quality clinical trial services to the pharmaceutical and biotechnology industries. Our commitment is to ensure that your clinical trials are conducted effectively and efficiently so that new and promising treatments become available to the millions of people battling these diseases. We are committed to facilitating the growing development needs of biotechnology companies in a world where increasingly, large conglomerated contract research organizations (CRO) are defining industry standards for clinical research. These CRO-defined "standards" are often excessive, or even at odds with current regulatory and international guidance, resulting in tangential focus, misleading project scopes, and unnecessary costs. It is our standard and privilege to ensure that new, promising oncology therapeutics are granted the attention, respect, and experienced teams that they deserve, without the cost or intimidation of a large CRO.